Sentences with phrase «cardiac cell therapy»

Cardiac cell therapy improves blood flow to the heart which can help reduce or improve your heart failure symptoms.

Cardiac cell therapy can be effective in improving your heart's function and reducing damage to heart tissue.

Cardiac cell therapy helps restore blood flow and repair damaged heart tissue without the risk of rejection.

Cardiac cell therapy stimulate the growth of new blood vessels in the heart to help restore blood flow to your heart.

Okyanos cardiac cell therapy targets the restoration of blood flow to the heart and repairs damaged heart tissue caused by heart attack or ischemic and non-ischemic heart disease.

The cardiac cell therapy field has experienced highs and lows in the last decade, received hundreds of millions of dollars in research money, and most recently been drawn into a university investigation.

Dr. Kattman is currently the Director of the Cardiac Cell Therapy Program for FujiFilm Cellular Dynamics International (FCDI).

Not exact matches

«We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient.»

We have found that exosomes and the cargo they contain are crucial mediators of stem cell - based heart regeneration, and we believe this might lead to an even more refined therapy using the «active ingredient» instead of the entire stem cell,» said Eduardo Marbán, MD, PhD, director of the Cedars - Sinai Heart Institute and a pioneer in developing investigational cardiac stem cell treatments.

Investigators at the Cedars - Sinai Heart Institute — whose previous research showed that cardiac stem cell therapy reduces scarring and regenerates healthy tissue after a heart attack in humans — have identified components of those stem cells responsible for the beneficial effects.

Several clinical trials are now investigating nitrite as a therapy for conditions such as heart attack, ruptured aneurysm, sickle cell pain crisis and cardiac arrest.

«We have built a team that is passionately focused on the potential of cell - based therapies to prevent, treat and cure life - threatening and debilitating diseases such as cardiac disease, cancer and macular degeneration,» said Richard Jove, Ph.D., director, NSU Cell Therapy Institute; chair and professor, Department of Biomedical Sciences, NSU M.D. College; and WSCS co-chcell - based therapies to prevent, treat and cure life - threatening and debilitating diseases such as cardiac disease, cancer and macular degeneration,» said Richard Jove, Ph.D., director, NSU Cell Therapy Institute; chair and professor, Department of Biomedical Sciences, NSU M.D. College; and WSCS co-chCell Therapy Institute; chair and professor, Department of Biomedical Sciences, NSU M.D. College; and WSCS co-chair.

Where treatment strategies have been exhausted, no - option patients may find hope for improvement of their condition with cardiac stem cell therapy for angina.

We accept referrals from physicians as well as inquiries from patients diagnosed with CAD, and of course welcome calls and questions from both physicians and patients about cardiac stem cell therapy and how the treatment is performed.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Our team of cardiologists follows stringent candidacy protocols for patients with heart disease seeking cardiac stem cell therapy.

Development of a comprehensive system which can enrich hPSC - CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

Specifically, application of a prefabricated cardiac tissue patch to prevent dilation and to improve pumping efficiency of the infarcted heart offers a promising strategy for making stem cell therapy a clinical reality.

Using state - of - the - art proteomics and associated computational methods, the Speicher laboratory is investigating protein changes associated with ovarian cancer, melanoma, cardiac injury resulting from breast cancer therapies, ectopic pregnancy, red cell diseases, and other clinical disorders.

Alison's residency project, Effects of Resuscitative Fluid Therapy on Cardiac Biomarkers was accepted for publication and her article entitled, Intranasal Mast Cell Tumor in the Dog: A Case Series, has been published in the Canadian Veterinary Journal.

Dr. Doris A. Taylor, PhD, Hon DSc, FAHA, FACC, Director of Regenerative Medicine Research for the Texas Heart Institute (THI), is one of the world's leading cell therapy and cardiac regeneration scientists.